■近年来,特应性皮炎(AD)的新疗法已在以色列上市,包括Christaborole,具有独特的苯并氧杂硼化学的小分子。
■为了描述基线特征,AD治疗史,以及在现实世界中使用早期criborole用户的医疗保健服务。
■使用以色列一家大型医疗服务提供者的数据进行了一项回顾性队列研究。包括自2019年7月至2020年9月底在以色列商业化以来接受crisaborole治疗的AD患者。基线人口统计学和临床特征,收集之前的AD相关治疗和医疗资源利用。
■共纳入441例患者(57.8%为女性,中位年龄=21.1y;四分位数间距=10.5-40.8)。在62.1%中,皮肤科医生开了第一个配药的crisaborole。从AD诊断到crisaborole治疗的中位时间为6.6年。在接受crisaborole治疗前12个月,低,中高效TCS的使用率为30.8%,31.1%和55.8%的患者,分别。在过去的5年中,与中度至重度AD相关的治疗被分配给38.5%的患者。哮喘和过敏性鼻炎分别为22.2%和37.2%,分别。在过去的一年里,患者平均9次主治医师就诊,84.6%就诊皮肤科医生(≥5次就诊:12.9%)。
■虽然crisaborole适用于轻度至中度疾病,结果表明,相当比例的患者有晚期AD治疗史,提示中重度AD.
UNASSIGNED: In recent years, new treatments dedicated to atopic dermatitis (AD) have become available in Israel, including crisaborole, a small molecule with unique benzoxaborole chemistry.
UNASSIGNED: To describe baseline characteristics, history of AD therapies, and use of health-care services of early crisaborole users in real-world settings.
UNASSIGNED: A retrospective cohort study was performed using the data of a large health provider in Israel. AD patients treated with crisaborole since it became commercially available in Israel in July 2019 through end of Sep 2020, were included. Baseline demographics and clinical characteristics, prior AD-related treatments and healthcare resource utilization were collected.
UNASSIGNED: A total of 441 patients were included (57.8% females, median age = 21.1y; interquartile range = 10.5-40.8). In 62.1%, a dermatologist prescribed the first dispensed crisaborole. Median time from AD diagnosis to crisaborole treatment was 6.6 years. Up to 12 months prior to crisaborole treatment, low-, mid- and high-potency TCS were used by 30.8%, 31.1% and 55.8% of patients, respectively. Treatments related to moderate-to-severe AD were dispensed to 38.5% of patients in the prior 5 years. Asthma and allergic rhinitis were documented among 22.2% and 37.2%, respectively. In the past year, patients had a median of 9 visits to primary care physicians, 84.6% visited a dermatologist (≥5 visits: 12.9%).
UNASSIGNED: While crisaborole is indicated for mild-to-moderate disease, results suggest that a significant proportion of patients had history of advanced AD therapies suggestive of moderate-to-severe AD.